Skip to main content

Want a detailed portfolio tracker?

DMII
NASDAQ
$10.08

Drugs Made In America Acquisition II Corp (DMII)

Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on identifying and merging with innovative players in the pharmaceuticals and biotechnology sectors, prioritizing advancements in domestic drug manufacturing. Leveraging a seasoned management team with considerable industry expertise, DMII aims to execute strategic transactions that respond to market dynamics and foster sustainable practices. The company's mission encompasses enhancing supply chain resilience and promoting U.S. healthcare self-sufficiency, ultimately driving long-term value creation for shareholders and contributing to the growth of the American pharmaceutical landscape.

This company is also listed under the following tickersDMIIR, DMIIU.

Market Cap

$504M

P/E Ratio

66.23

Free Cash Flow Yield

-0.04%

Beta (5Y)

-0.01

Price Chart

Valuation
Market Cap$504M
P/E66.23
P/B1.31
Profitability
Gross Profit (TTM)-$812K
EBITDA-$326K
EPS$0.15
Financial Health
Debt-to-Equity0.1%
Free Cash Flow Yield-0.04%
Growth & Risk
Beta (5Y)-0.01
Sharpe Ratio-0.26